LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Rhea-AI Summary

LENZ Therapeutics (Nasdaq: LENZ), a pre-commercial stage biopharmaceutical company, has scheduled its first quarter 2025 financial results and corporate highlights webcast for May 7th, 2025, at 4:30 p.m. EDT.

The company specializes in developing an innovative aceclidine-based eye drop designed to enhance near vision for individuals with presbyopia, positioning it as the first and only treatment of its kind.

Interested participants can join via:

• Phone: (800) 715-9871 (Domestic)
• Phone: (646) 307-1963 (International)
• Access Code: 8251197

The webcast will be accessible through the company's website at www.LENZ-tx.com in the Investors & Media section, with a replay available for 30 days following the event.

Positive

• First and only aceclidine-based eye drop for presbyopia, indicating potential market exclusivity
• Pre-commercial stage indicates progress towards market readiness

Negative

• Pre-revenue status with no current commercial products
• Likely ongoing R&D expenses without revenue generation

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights.

To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 8251197. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.

About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.

Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

FAQ

When will LENZ Therapeutics (LENZ) report Q1 2025 earnings?

LENZ Therapeutics will report its Q1 2025 financial results on Wednesday, May 7th, 2025, at 4:30 p.m. EDT via a webcast.

How can investors join LENZ Therapeutics Q1 2025 earnings call?

Investors can join by dialing (800) 715-9871 (Domestic) or (646) 307-1963 (International) with code 8251197, or access the live webcast through LENZ-tx.com in the Investors & Media section.

What is LENZ Therapeutics main product focus?

LENZ Therapeutics is developing the first and only aceclidine-based eye drop designed to improve near vision in people with presbyopia.

How long will LENZ Q1 2025 earnings webcast be available?

The webcast replay will be available on LENZ Therapeutics website for 30 days following the May 7th, 2025 event.

What stage is LENZ Therapeutics in its development?

LENZ Therapeutics is currently in the pre-commercial stage as a biopharmaceutical company.